In a recent speech, Democratic presidential nominee Joe Biden reaffirmed his position that people convicted of low-level drug offenses should be forced into rehabilitation in order to stay out of jail and get their records cleared.
While the former vice president seems to view the policy as a progressive alternative to incarceration, many drug reform advocates feel mandatory treatment reinforces misconceptions about substance misuse, and they point out that the efficacy of forced rehabilitation programs are scientifically questionable.
“Anybody who gets convicted of a drug crime—not one that is in terms of massive selling, but consumption—they shouldn’t go to prison. They should go to mandatory rehabilitation,” Biden said at a campaign event in Kenosha, Wisconsin last week. “Instead of building more prisons, as I’ve been proposing for some time, we build rehabilitation centers.”
“Mandatory. They’ve got to go to mandatory rehab, but it’s not part of the record when they get out if they finish it,” he said, adding that having a criminal record often prevents people from obtaining housing, financial aid for school and other public benefits.
It’s not clear whether Biden feels that people with low-level marijuana convictions should similarly be subject to mandatory rehabilitation. He’s proposed decriminalizing cannabis possession, but theoretically the rehab policy could fit within the framework he’s envisioning for a decriminalization policy that stops short of full legalization, which he opposes. Marijuana Moment reached out to his campaign for clarification, but a representative did not immediately respond.
In any case, mandatory rehabilitation is not the policy of choice for most drug reform advocates.
“Coerced treatment will inevitably result in forcing people who do not have substance use disorders or who would naturally recover into services,” Maritza Perez, director of national affairs at Drug Policy Action, told Marijuana Moment in response to Biden’s comments. “The overwhelming majority of people who use drugs do not develop a substance use disorder. Of those that do, most recover without participating in any formalized treatment or recovery services.”
“Additionally, mandatory treatment can have a net-widening effect, continuing to trap people under an alternative form of state surveillance,” she said. “Instead we must expand access to substance use disorder treatment and other support services that are attractive and affordable to increase voluntary treatment where appropriate. Biden’s proposal would merely waste resources that could be used for people who actually want and could benefit from treatment.”
Biden just said he’d push for mandatory rehab for drug possession, with the charge cleared if you complete the program. This isn’t reform. Possession does not mean addiction.
— Radley Balko (@radleybalko) September 3, 2020
This isn’t the only policy where Biden and drug reform advocates don’t see eye-to-eye. The nominee remains opposed to marijuana legalization despite supermajority support among voters. Instead, he supports decriminalizing cannabis possession, legalizing medical marijuana, expunging prior convictions and letting states set their own policies.
A senior adviser to Biden also said recently that his administration would pursue decriminalization and automatic expungements for prior marijuana convictions if he is elected.
Biden’s vice presidential running mate Sen. Kamala Harris (D-CA) similarly raised eyebrows in drug policy circles in a recent interview, lamenting racial disparities in cannabis enforcement without acknowledging her own record as a prosecutor who oversaw thousands of marijuana cases. Despite her past efforts to campaign against marijuana legalization in California as a candidate for state attorney general, she’s now the lead Senate sponsor of a bill to federally legalize cannabis. But despite her newfound support, Harris has indicated that she won’t be proactively pushing Biden to adopt a pro-legalization stance.
Earlier this year, Biden and Sen. Bernie Sanders (I-VT) established a criminal justice task force that issued various recommendations on policies they feel should be adopted. Advocates hoped the panel would push the former vice president to back legalization, but that didn’t materialize.
Meanwhile, the Democratic National Committee’s (DNC) platform committee rejected an amendment to make legalization a 2020 party plank. Some suspect this was because the panel didn’t want to endorse a policy that’s at odds with that of the nominee.
Democratic lawmakers have expressed confidence that Congress will deliver on legalization regardless of the Biden administration position on the issue.
House Democratic leadership recently announced that the chamber will vote its version of Harris’s comprehensive legalization bill later this month, setting the stage for a potential conflict with Biden if he’s asked to respond.
Sen. Ed Markey (D-MA), who recently won his primary battle against Rep. Joe Kennedy III (D-MA), said last month that legalization will be at the forefront of the congressional agenda in 2021 if Biden and Harris are elected. He also said during a separate interview in July that Congress will advance marijuana reform regardless of Biden’s stance.
Congressional Cannabis Caucus cochair Rep. Barbara Lee (D-CA), who was among the DNC platform committee members who surprisingly voted against the legalization amendment, said last week that the former vice president is going to need to evolve on marijuana policy and support legalization.
On the Republican side of the election, President Trump’s reelection campaign has been consistently attacking Biden over his record authoring punitive anti-drug laws in the Senate. They’ve cast him as an “architect” of the drug war while attempting to frame Trump as the criminal justice reform candidate. That’s despite the fact that the president’s administration has taken several hostile actions on the marijuana front that stop short of a full-scale crackdown on businesses in legalized states.
Last month, the president also urged Republicans not to place marijuana legalization initiatives on state ballots out of concern that it will increase Democratic turnout in elections.
Photo courtesy of Flickr/Marc Nozell.
USDA Appoints Another Hemp Executive To Trade Advisory Committee
Another hemp industry executive has been appointed to a federal advisory committee under the U.S. Department of Agriculture (USDA) and U.S. Trade Representative (USTR).
Patrick Atagi, chairman of the board at the National Industrial Hemp Council (NIHC), will serve as a member of USDA’s Agricultural Technical Advisory Committee for Trade in Tobacco, Cotton and Peanuts, the organization announced on Friday.
He’s the second member of NIHC to join a USDA and USTR advisory panel. Kevin Latner, vice president of marketing for the group, was appointed to the Agricultural Technical Advisory Committee for Trade in Processed Foods in July.
In their federal advisory roles, the NIHC officials will focus on advocating for trade policies that benefit the burgeoning hemp market.
“I want to thank outgoing USDA Secretary Sonny Perdue for his confidence and look to working with Biden Administration Secretary-designate Tom Vilsack and USTR-designate Katherine Tai,” Atagi said in a press release. “It’s an honor to be asked to serve and I look forward to representing the hemp industry.”
These appointments come at a pivotal time, as USDA just last week released its final rule setting out the federal regulations for hemp that will take effect in March. With two industry experts advising the federal agency, they could bring unique insights that further promote market growth.
Early versions of the agency’s proposed regulations were met with mixed reviews from industry stakeholders. While many appreciated USDA’s efforts to stand up the market, there was widespread criticism from businesses and lawmakers over certain provisions viewed as excessively restrictive such as testing requirements and THC limits.
The final rule doesn’t include everything stakeholders sought, but there were some modifications made throughout the process, including adding flexibility in THC testing and extending the sampling window.
These aren’t necessarily areas where the NIHC appointees will be directly involved, but they could help inform regulations from a trade perspective.
Under a trade deal signed last year, China will be required to buy a lot more hemp from the U.S.
Even as USDA crafted its rules and built up these advisory committees, it has spent past months reviewing and approving numerous state and tribal regulatory proposals—most recently for Rhode Island.
Biden Transition Team Highlights Top Health Pick’s Medical Marijuana Work
President-elect Joe Biden’s new pick for a leading role in the U.S. Department of Health and Human Services (HHS) is a strong ally of the medical marijuana community—the latest pro-reform selection to be named in recent weeks.
Rachel Levine, who currently serves as Pennsylvania’s health secretary, is being nominated for assistant secretary of HHS. And the Biden transition team isn’t shying away from her connection to medical cannabis, noting her expertise on the topic in a press release on Tuesday.
“In addition to her recent posts, Dr. Levine is also an accomplished regional and international speaker, and author on the opioid crisis, medical marijuana, adolescent medicine, eating disorders, and LGBTQ+ medicine,” Levine’s official biography states.
Of course, the president-elect is in favor medical cannabis, in addition to a number of other more modest reform proposals such as rescheduling, decriminalizing possession, expunging prior marijuana records and letting states set their own policies. But given his ongoing opposition to adult-use legalization, the cannabis mention on his site is noteworthy.
Pennsylvania Gov. Tom Wolf (D) reacted to Biden’s selection by emphasizing Levine’s cannabis work, noting that during her time in the state’s health department, she “was instrumental in establishing the state’s medical marijuana program, bringing national awareness to opioid use disorder, and highlighting and promoting the need for adequate medical care and access for the LGBTQ community.”
Michael Bronstein, president of the American Trade Association for Cannabis & Hemp, similarly said in a press release that Levine “is a trailblazer who successfully guided the implementation of Pennsylvania’s medical marijuana program.”
“Under Dr. Levine’s leadership, the program expanded qualifying conditions based on science, added flower to help meet patient needs, and stood up a first in the nation marijuana research program,” he said. “Pennsylvania is now one of the quickest growing and most consequential medical marijuana markets in the country in large part due to Dr. Levine’s work.”
In one of the more recent actions in her current role, the health department head oversaw temporary changes to the state’s medical cannabis program in response to the coronavirus pandemic. That included eliminating restrictions on the number of patients a registered caregiver can work with.
“In the midst of COVID-19, we need to ensure medical marijuana patients have access to medication,” she said in March. “We want to be sure cardholders in the medical marijuana program can receive medication for one of 23 serious medical conditions during this difficult time.”
Levine, who would also be the first openly transgender Senate-confirmed federal official, would be serving in an agency that plays a significant role in setting federal marijuana policy. While the Justice Department broadly dictates marijuana’s federal scheduling, a medical and scientific review by HHS is binding on the attorney general’s subsequent classification decision.
Biden’s pick to lead HHS, California Attorney General Xavier Becerra (D), is also amenable to reform.
The president-elect also recently nominated former South Carolina Democratic Party Chair Jaime Harrison to lead the Democratic National Committee—and he’s a strong backer of full marijuana legalization.
Biden announced earlier this month that he wants Rhode Island Gov. Gina Raimondo (D) to run the Commerce Department. The governor came out in support of legalization in 2019, and she released a budget proposal last year that called for a state-run regulatory model for cannabis.
For attorney general, Biden is nominating Judge Merrick Garland, who has not been especially outspoken about his views on marijuana policy. While advocates expressed concern about his commentary in a 2012 federal appeals case on marijuana scheduling, he doesn’t appear to have been publicly hostile to a policy change.
In other positive news for advocates, the president-elect is also set to nominate former prosecutor and civil rights activist Vanita Gupta as associate attorney general. She favors cannabis legalization and has strongly condemned harsh criminalization policies for non-violent drug offenses.
New York Governor Says Budget Uses Marijuana Revenue For Social Equity, With Details Forthcoming
New York Gov. Andrew Cuomo (D) on Tuesday previewed expected revenue from a legal marijuana program he’s proposing through his annual budget, with more detailed legislative language set to be released later in the day.
The governor has repeatedly argued that taxing and regulating cannabis will help fill a historic, $15 billion budget deficit. And while the projected $350 million in annual revenue from marijuana taxes won’t resolve the problem on its own, it represents one opportunity to boost an economy that has suffered amid the coronavirus pandemic.
“We also propose legalizing adult-use cannabis, which would raise about $350 million,” Cuomo said in his budget speech, adding that “$100 million would go to a social equity fund. That would still give us $250 million towards the budget and our needs.”
A briefing book for the governor’s budget states that legalization should be enacted “for the purposes of fostering and promoting temperance in their consumption, to properly protect the public health, safety, and welfare, and to promote social equality.”
Watch Cuomo discuss his marijuana legalization proposal below:
While it’s not immediately clear what that social equity fund would entail, it’s a notable component that advocates are closely monitoring. An outline of his budget plan similarly said the proposal will “correct past harms by investing in areas that have disproportionally been impacted by the war on drugs.”
In the briefing book, the governor calls for three types of taxes on recreational cannabis products: one based on THC content to be applied at the wholesale level, a 10.25 percent surcharge tax at the point of purchase by consumers and applicable state and local sales taxes.
The THC potency tax is intended to “more accurately capture both the true market value and the potential public health risks associated with the final cannabis product,” the governor’s office said, and it will be applied as follows:
“Cannabis flower/pre-roll/shake products are taxed at a rate of 0.7 cent per milligram of THC content. Cannabis concentrates/oil products are taxed at a rate of 1 cent per milligram of THC content, while cannabis infused/edible products are taxed at a rate of 4 cents per milligram of THC content.”
“Of the THC-based tax, retail surcharge, and any license fees, the first $10 million in FY 2023, $20 million in FY 2024, $30 million in FY 2025, $40 million in FY 2026, and $50 million annually thereafter are directed for social equity purposes, with the remainder directed to the newly established New York State Cannabis Revenue Fund,” it states.
A press release from the governor’s office clarifies that $100 million equity figure Cuomo mentioned in his speech is the aggregate funding over the first four years. “These monies will be used to support individuals and communities that have been the most harmed by decades of cannabis prohibition,” it says.
New York Budget Director Robert Mujica similarly said during a follow-up briefing on Tuesday that the social equity effort will support “communities that have been harmed by the nation’s policies with relation to cannabis.”
“As far as the cannabis and social equity fund, that is in the statute—we would have a permanent funding going program,” he said. “So as the program ramps up, a portion of the funding will go $100 million, and then there’ll be an ongoing fund once it ramps up to continue those investments.”
Further, the governor’s briefing book notes that the existing medical cannabis excise tax will continue, as well as “the current revenue distributions for an additional seven years and directing the currently undistributed 45 percent of tax revenue to the newly established New York State Cannabis Revenue Fund.”
The administration also estimates that the equivalent of 208 full-time jobs will be added to the Division of Alcoholic Beverage Control to support the new Office of Cannabis Management, which will be charged with regulating and issuing licenses for the new recreational marijuana market as well as those for medical cannabis and hemp.
Cuomo has twice pitched legalization through the budget, but reform legislation has stalled in part because of disagreements about how to allocate tax revenue. The governor has generally favored putting the monies in the state’s general fund, while leading legislators and activists have pushed for a more targeted distribution centering communities most impacted by the drug war.
If the outline and this latest speech are any indication, it seems Cuomo may be coming around to the latter proposal. But again, the full details of the plan will come when actual legislative language is released later on Tuesday.
In any case, the legislature will have more influence this year after Senate Democrats secured a supermajority in the November election. If the governor were to veto any bill over details he didn’t like, they could potentially have enough votes to override him.
There’s growing recognition within the legislature about the seeming inevitability of marijuana reform this year, regardless of differing opinions on the specifics.
The top Republican in the New York Assembly said last month that he expects the legislature to legalize cannabis this coming session.
Senate Majority Leader Andrea Stewart-Cousins (D) said in November that she also anticipates that the reform will advance next year, though she noted that lawmakers will still have to decide on how tax revenue from marijuana sales is distributed.
Cuomo also said that month that the “pressure will be on” to legalize cannabis in the state and lawmakers will approve it “this year” to boost the economy amid the health crisis.
The push to legalize in New York could also be bolstered by the fact that voters in neighboring New Jersey approved a legalization referendum in November.
Legislators prefiled a bill to legalize cannabis in New York earlier this month. The legislation, introduced in the Senate by Sen. Liz Krueger (D) and 18 other lawmakers, is identical to a version she filed last year that did not advance.
Separately, several other bills that focus on medical marijuana were recently prefiled in New York, and they touch on a wide range of topics—from tenants’ rights for medical cannabis patients to health insurance coverage for marijuana products.
This story has been updated to include comments from the budget director and details about the legalization proposal outlined in the briefing book.